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This journal is ª The Royal Society ofSynthesis, structure–activity relationships and
stereochemical investigations of new tricyclic
pyridazinone derivatives as potential STAT3 inhibitors†
Daniela Masciocchi,a Arianna Gelain,a Federica Porta,a Fiorella Meneghetti,a
Alessandro Pedretti,a Giuseppe Celentano,a Daniela Barlocco,a Laura Legnani,be
Lucio Toma,b Byoung-Mog Kwon,c Akira Asaid and Stefania Villa*a
Through a cell-based biological screening, the benzocinnolinone derivative ()-2c was identiﬁed as a
promising STAT3 inhibitor. Since SAR studies on a series of compounds structurally related to ()-2c (1c,
2a–p, 3c, 4c, 6) showed that the latter had the most signiﬁcant inhibitory activity, we investigated in
depth its essential structural features. In particular, enantiomeric separation was performed, and the
absolute conﬁguration of the stereoisomers was assigned by theoretical and crystallographic studies.
The biological evaluation highlighted that (S)-()-2c is twice as potent as (R)-(+)-2c.Introduction
Signal Transducer and Activator of Transcription 3 (STAT3) is a
member of STAT family that comprises seven isoforms (STAT1-
4, 5a, 5b, 6). They directly relay signals from the cytoplasmic
membrane to the nucleus1 and regulate transcription of target
genes. STAT activation is triggered by many cytokines and
growth factors including epidermal growth factor (EGFR),
platelet-derived growth factor (PDGF), IL-6, as well as oncogenic
proteins such as Src and Ras and, in addition, several carcino-
gens (e.g. cigarette smoke, diesel exhaust).2 Numerous pub-
lished reports have shown that blocking constitutively activated
STAT3 signaling leads to apoptosis of tumor cells,3–5 but has
only minimal eﬀects on normal cells.6,7 This selective inhibition
might reect an irreversible dependence of tumor cells on the
high level of STAT3 for growth and survival, whereas normal
cells might be able to withstand lower level STAT3 activity or use
alternative signaling pathways. Therefore, the design of newUniversita` degli Studi di Milano, Via
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Chemistry 2013molecules as STAT3 inhibitors, their synthesis and the studies
of their interaction with the target are very important for the
development of new anticancer drugs endowed with interesting
pharmacodynamic properties and reduced side eﬀects.8
There are two diﬀerent approaches to inhibit STAT3
signaling: direct (by the interaction of the compounds with the
protein) or indirect (by blocking the upstream molecules). The
direct inhibitors can be divided into several classes, e.g.
peptides, peptidomimetics, natural compounds, small mole-
cules and oligonucleotides, while the indirect ones can be
classied as either natural or synthetic compounds.8 A few
representative STAT3 inhibitors, endowed with high activity, are
reported in Chart 1. STA21 (I, the rst non-peptide inhibitor)
and CDDO-Me (II, a synthetic triterpenoid derivative) are both
in clinical trials;9 the orally bioavailable derivative of STX-0119
(III, a quinoline analogue tested in vivo)10 and compound
HJC0123 (IV)11 were recently reported while the natural
compound Cryptotanshinone (V), isolated from Salvia miltior-
rhiza, initially utilized for the treatment of circulatory disorders
was later investigated for STAT3 inhibition.12 During our
ongoing research,13,14 aimed at the design and synthesis of new
non-peptide small molecules as potential STAT3 inhibitors, we
screened our internal library using the dual luciferase assay in
HCT-116 cells; compound 2c [ethyl 4-(3-oxo-4,4a,5,6-tetra-
hydrobenzo [h] cinnolin-2(3H)-yl)butanoate] (Chart 2) showed
interesting inhibitory activity (46% at 2 mM).
Given the apparent similarity between our tricyclic hit and
Cryptotanshinone, an introductory conformational study was
done on the two compounds. Particular attention was focused
on the exibility of the natural compound and on the possible
inversion of the central ring of 2c. Preliminary results seemed to
indicate that both structures are quite rigid and characterizedMed. Chem. Commun., 2013, 4, 1181–1188 | 1181
Chart 2
Chart 1
MedChemComm Concise Articleby planarity, an important requisite for the inhibitory activity
versus STAT3 (unpublished results).
On this basis, since preliminary modications on 2c, e.g.
homologation to the corresponding indenopyridazinone 1c and
benzocycloheptapyridazinone 3c as well as introduction of a 4–4a
double bond (4c) proved to be detrimental, the following SAR
studies were performed on this hit. In particular, chains of
diﬀerent nature and length (2a,b,f–p) as well as substitution of
the phenyl ring (2d,e) were investigated. All the synthesized
compounds were tested by the cell-based dual luciferase assay, at
the concentration of 2 mM, in order to determine their ability to
lower STAT3 activity. Subsequently, we separated the enantio-
mers of 2c to investigate the inuence of the stereocenter on its
biological activity. In parallel, modeling studies were performed
to explore the conformational properties of this class and to
understand how themolecular features inuenced the [a]D value,
taking into account the experimental [a]D of the single1182 | Med. Chem. Commun., 2013, 4, 1181–1188enantiomers. This allowed the theoretical assignment of the
conguration of the stereocenter of 2c. The absolute congura-
tion was then conrmed bymeans of crystallographic analysis on
the suitable derivative (+)-13, containing a chlorine atom.
Compound 13 is related to 2c since both are synthesized via N-2
alkylation of 6, which occurs with retention of conguration. In
summary, we obtained (+)-13 from (+)-6, and ()-2c from ()-6.Chemistry
The synthesis of the ester derivatives 1c, 2a–h and 3c, charac-
terized by ve, six and seven-carbon atom central rings respec-
tively, was performed through alkylation at the N-2 position of
the required pyridazinone,15,16 with suitable bromo ester chains,
as shown in Scheme 1. 2b and 2c were easily hydrolyzed into the
corresponding acids 2i and 2j and 2j was subsequently converted
to the ethyl amide 2k. The amino derivative 2lwas prepared from
6 by alkylation of 1,4-dibromobutane under microwave irradia-
tion followed by condensation with ethylamine. The alkyl deriv-
atives 2m and 2n were obtained through alkylation of 6 with the
required bromo derivative. Compound 2o was synthesized by
alkylation of 6 with 1-chloropropanol to give intermediate 10,
which was rstly coupled with N-Boc-Phe-OH and then depro-
tected to form 2o. For the synthesis of the derivative 2p, benzo-
cinnolinone 6was alkylated with 4-bromobutyronitrile and the so
obtained nitrile 12 was converted to the tetrazole 2p. During the
synthesis of 4c, compound 6 was rstly oxidized to 5,6-dihy-
drobenzo[h]cinnolin-3(2H)-one 8, following a previously
described procedure15 and subsequently alkylated with ethyl 4-
bromobutanoate. Finally, the enantiomeric separation was per-
formed on ()-2c using a chiral semi-preparative HPLC (Chiralcel
OJ, 10 mm, 250  4.6 mm); the two stereoisomers were obtained
as oils with ee > 99% and were characterized by [a]D values of
+374 and 365. In parallel, the enantiomeric separation of the
intermediate ()-6 was performed using the same conditions,
obtaining two enantiomers characterized by [a]D values of +572
and561, respectively. Enantiomer ()-6was alkylated with ethyl
4-bromo-butanoate under microwave irradiation to give ()-2c
(see the Experimental part). Following the same procedure, by
treatment of (+)-6 with 2-bromo-1-chloroetane, compound (+)-13
was obtained (Scheme 1).Results and discussion
Compounds 1c, 2a–p, 3c, 4c, and 6 were tested by a dual-lucif-
erase assay17 at a concentration of 2 mM inHCT-116 cells aer 24
h of treatment. Their activities were compared to that of the
natural compound Cryptotanshinone and the results are
reported in Table 1. As can be seen, each modication on 2c,
namely elimination (6), shortening (2b) or elongation (2f) of the
ester chain, as well as its substitution with alkyl moieties (2m)
caused a decrease in the activity. Similarly, hydrolysis of the
ester group (2j) or its substitution by diﬀerent functionalities
(2k,l,o,p) had a detrimental eﬀect. These results highlight the
importance of the chain at the N-2 position and of its nature.
Also the presence of diﬀerent substituents on the phenyl ring
(2d,e) did not prove to be benecial.This journal is ª The Royal Society of Chemistry 2013
Scheme 1 Reagents and conditions: (i) Br(CH2)nCOOCH2CH3, NaH, dry DMF, 70 C, 15 h; (ii) NaOH/H2O, EtOH, reﬂux, 2 h; (iii) EtNH2 70% in water, HATU, N-methyl-
morpholine, rt, 1.5 h; (iv)m-nitrobenzensulfonic acid sodium salt, NaOH, H2O, reﬂux, 0.5 h; (v) Br(CH2)3COOCH2CH3, KOH, TBAF, toluene, 50 C; (vi) Br(CH2)4Br, NaH, dry
DMF, MW 60 C, 10 min; (vii) 70% EtNH2 in water, Et3N, DMF, 90–100 C, 7 h; (viii) Br(CH2)nCH3, NaH, dry DMF, 70 C, 10 h; (ix) Cl(CH2)3OH, NaH, dry DMF, 60 C, 4 h; (x)
N-Boc-Phe-OH, HATU, N-methyl-morpholine, rt, 24 h; (xi) triﬂuoroacetic acid, CH2Cl2, rt, 3 h; (xii) Br(CH2)3CN, dry DMF, NaH, 50 C, 3 h; (xiii) NaN3, ZnBr2 isopropanol/
H2O 1 : 2, MW 170 C, 1 h; (xiv) Br(CH2)2Cl, NaH, dry DMF, MW 70 C, 15 min.
Concise Article MedChemCommIt should be noted that the alpha-screen based assay18 did
not show any signicant interaction between 2c and the STAT3
SH2 domain, therefore 2c should be considered as an indirect
inhibitor.
When the enantiomers of 2c were investigated by the lucif-
erase assay at 10 mM concentration, ()-2c resulted to be about
two-fold more potent than (+)-2c, as shown in Fig. 1.
As the two stereoisomers of 2c (Chart 2) were obtained as
oils, their absolute congurations were initially assigned
through theoretical calculations. Preliminary modeling studies
were carried out, as the complete knowledge of the allowed
conformations of 2c is a necessary pre-requisite for the optical
rotation theoretical prediction. All the calculations were carried
out at the B3LYP/6-311+G(d,p) level. The tricyclic moiety was
shown to assume a geometry in complete agreement with that
described in a previous paper and obtained with a molecular
mechanics approach.19 The main degree of conformational
freedom is represented by the N2 side chain that was shown to
be able to assume two almost isoenergetic orientations, char-
acterized by values of s1(N1–N2–C10–C20) of84 and 78 to give
conformers A and B, respectively (Fig. 2).
Starting from the located conformations, the specic optical
rotation of stereoisomer (R)-2c was predicted using DFT calcu-
lations at the same level as above.20 The calculated [a]D of theThis journal is ª The Royal Society of Chemistry 2013two conformations A and B of (R)-2c were +419 and +682,
respectively, in reasonable agreement with the experimental
value, allowing to assign the R conguration to (+)-2c. Because
of the high value of the specic rotation and the large inuence
of the N2 side chain on it, we performed new DFT calculations
in order to evaluate the contribution of the molecular
substructures. In summary, we investigated: (i) the intrinsic
properties of the pyridazinone system exemplied by 14 (Fig. 3)
and (ii) the eﬀect of the presence and orientation of a phenyl
group linked to the pyridazinone as in compound 15 (Fig. 3).
Compound 14 shows a value of [a]D ¼ +292, while 15, charac-
terized by the almost planar arrangement of the two rings
(s2(C10–C10a–C10b–N1) ¼ 14), exhibits an optical rotatory
power signicantly increased ([a]D ¼ +731).
In addition, with the aim of identifying the relationship
between the mutual orientation of the two rings and [a]D, we
determined the energy prole for rotation around the C–C bond
linking the two rings, calculating [a]D for every step of the scan
(the resulting prole is reported in Fig. S1 of the ESI†). In the
nearly planar molecular arrangements, characterized by s2¼ 0,
30, +150, and 180, [a]D presents high values, i.e. +679,
+764, +719, and +701, respectively. By contrast, the perpendic-
ular arrangement of the phenyl and pyridazinone rings causes a
lowering of [a]D, that is +238 for s2¼90 and +221 for s2¼ 90.Med. Chem. Commun., 2013, 4, 1181–1188 | 1183
Table 1 Physico-chemical and biological data for compounds 1–4, and 6
Compound R R1]R3 R2 n
C at
position 4 Eluenta Yield (%) Mp (C)
Inhibitory
activityb (%)
Cryptotanshinone 25
1c (CH2)3COOEt H H 1 CH2 B 55 Oil 28
2a (CH2)COOEt H H 2 CH2 C 71 Oil 3
2b (CH2)2COOEt H H 2 CH2 B 61 Oil 30
2c (CH2)3COOEt H H 2 CH2 A 60 Oil 46
2d (CH2)3COOEt OCH3 H 2 CH2 B 56 96–97 23
2e (CH2)3COOEt H Cl 2 CH2 C 60 45 9
2f (CH2)4COOEt H H 2 CH2 C 65 Oil 21
2g (CH2)5COOEt H H 2 CH2 B 70 Oil 25
2h (CH2)6COOEt H H 2 CH2 B 70 Oil 22
2i (CH2)2COOH H H 2 CH2 A 97 195–196 2
2j (CH2)3COOH H H 2 CH2 A 95 166–166 8
2k (CH2)3CONHEt H H 2 CH2 A 83 136–137 16
2l (CH2)4NHEt H H 2 CH2 A 50 Oil 3
2m (CH2)3CH3 H H 2 CH2 D 75 Oil 9
2n (CH2)4CH3 H H 2 CH2 D 80 Oil 22
2o (CH2)OPhe H H 2 CH2 B 50 Oil 12
2p H H 2 CH2 A 46 Oil 9
3c (CH2)3COOEt H H 3 CH2 C 40 Oil 12
4c (CH2)3COOEt H H 2 CH B 98 Oil 1
6 H H H 2 CH2 — — Oil 6
a Eluent: (A) dichloromethane/methanol 95 : 5; (B) dichloromethane/ethyl acetate 6 : 4; (C) petroleum ether/ethyl acetate 7 : 3; (D) petroleum ether/
ethyl acetate 9 : 1. b The inhibitory activity of the compounds against STAT3 was evaluated using the dual-luciferase assay in HCT-116 cells at a
concentration of 2 mM aer 24 h of treatment. The values of STAT3 inhibitory activity were the means of 3 experiments and the maximum
deviation from the mean was less than 10%.
Fig. 1 Dual-luciferase assay results of compounds ()-2c, ()-2c, and (+)-2c. The
test was carried out in the HCT116 cell line after 24 h treatment with the selected
compound (10 mmol L1).
Fig. 2 Three-dimensional plots of conformations A and B of compound 2c.
Fig. 3 Three-dimensional plots of compounds 14 and 15.
MedChemComm Concise ArticleThese results suggest that higher values of [a]D are related to a
greater conjugation of the system.
To give support to the theoretical predictions, the absolute
conguration of (+)-2c was conrmed by means of crystallo-
graphic analysis on the suitable derivative (+)-13. We selected1184 | Med. Chem. Commun., 2013, 4, 1181–1188 This journal is ª The Royal Society of Chemistry 2013
Fig. 4 ORTEP17 view of the asymmetric unit of (+)-13 and the relative atom-
numbering scheme (thermal ellipsoids at 50% probability).
Concise Article MedChemCommthe ethylenic chain to introduce the chlorine atom on (+)-6, as
the quality of the crystals for derivatives of this family tended to
worsen with longer chains (data not published). Therefore, we
considered the ethylenic chain as the compromise for balancing
the contrast between the rigid core and the lateral exible chain.
In fact, well diﬀracting crystals of compound (+)-13 were
obtained, which allowed its crystal structure determination.
The ORTEP21 view of (+)-13 is shown in Fig. 4.
The chlorine atom gives a signicant anomalous dispersion
contribution to l MoKa permitting the unambiguous attribu-
tion of the absolute conguration R to the enantiomer (+)-13.
The tricyclic skeleton of the compound consists of three fused
rings slightly twisted with respect to each other. The dihedral
angles between their least-square planes a (C1/N1/N2/C4/C3/
C2), b (C3/C4/C5/C6/C7/C8) and g (C5/C6/C12/C11/C10/C9) are
a–b ¼ 7.0(1), a–g ¼ 16.3(1), b–g ¼ 10.0(1), respectively (the
arbitrary atom-numbering scheme used in Fig. 4). Therefore,
the dihydropyridazinone ring adopts an intermediate geometry
between a twisted-boat and a half-chair conformation quanti-
tatively dened by the Cremer & Pople parameters22 QT ¼
0.430(5) A˚, f ¼ 80.0(8), and q ¼ 109.0(6), while the central
six-membered ring is almost in a half-boat conformation,
characterized by the puckering parameters QT ¼ 0.504(6) A˚, f ¼
67.4(7) and q¼ 58.0(5), with the ap atom C8 out of the best
mean plane calculated over the other ve carbons by 0.672(6) A˚.
The orientation of the lateral chain is dened by the torsion
angle N2–N1–C13–C14 of 68.7(1) that corresponds to the value
found in the B conformer of (R)-2c resulting from the modeling
studies, even though the latter has a much longer side chain.Fig. 5 Intermolecular interactions of (+)-13.
This journal is ª The Royal Society of Chemistry 2013In the crystal, the molecules are attened almost parallel to
the plane containing the b and c axes and are connected through
weak Cp–H/O contacts between C9–H9/O1I at a distance of
2.66(3) A˚ and angle of 148(1) (I at 3/2  x, 1  y, z  1/2) (Fig. 5).
Finally, in light of the unambiguous assignment of the
absolute conguration to (+)-13 and hence to the 2c stereoiso-
mers, the enantiomer (S)-()-2c was found to be twice as potent
as(R)-(+)-2c in the luciferase assay.Conclusion
In an attempt to identify new small molecules as potential STAT3
inhibitors, we screened our internal library using a dual lucif-
erase assay, and found promising activity for the benzocinnoli-
none derivative 2c. Since SAR studies on a series of related
pyridazinones did not show any improvement in the activity, we
focused our attention on the stereocenter of 2c. In summary, we
resolved ()-2c into its enantiomers, which were tested by the
luciferase assay in comparison with the racemate. Compound
()-2c resulted to be about two-fold more potent than (+)-2c. In
order to assign the absolute conguration to the enantiomers,
their optical rotatory power was estimated through calculations
that allowed us to theoretically assign the R conguration to
(+)-2c. This result was then experimentally conrmed through
X-ray analysis on the enantiomerically pure derivative (+)-13,
structurally related to (+)-2c. The crystallographic study unam-
biguously attributes the R conguration to the dextrorotatory
enantiomer. On this basis, we could conclude that (S)-()-2c is
endowed with better inhibitory activity in the luciferase assay.Experimental section
Materials and methods
Reagents were purchased from Sigma-Aldrich and were used
without any further purication. All reactions involving air-
sensitive reagents were performed under a nitrogen atmosphere.
The reaction was carried out either under conventional condi-
tions or by means of a Biotage-Initiator microwave synthesizer.
Melting points were determined in open capillary tubes on a
Bu¨chi Melting Point B-540. Proton NMR spectra were acquired at
ambient temperature on a Varian 300 MHz Oxford instrument.
Chemical shis are expressed in ppm from tetramethylsilane
resonance in the indicated solvent (TMS: 0.0 ppm). 1H NMR data
are reported in the following order: ppm, multiplicity (s, singlet;
d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), and
number of protons (see ESI†). The course of the reaction was
monitored by thin layer chromatography (TLC) on aluminum-
backed Silica Gel 60 plates (0.2 mm, Merck). Intermediates and
nal compounds were puried by ash chromatography using
Merck Silica Gel 60 (70–230mesh). The purity of nal compounds
was determined by HPLC analysis and was $95%. The enantio-
meric separation of compounds was performed using a chiral
semi-preparative HPLC: Chiralcel OJ (10 mm, 250  4.6 mm).
Optical rotation values of the enantiomers were registered on a
Perkin Elmer instrument (Mod 343) at 589 nm and 25 C.
General procedure A for the synthesis of the alkylated
derivatives (1c, 2a–h, 2m,n, 3c, 10, 12). A solution of theMed. Chem. Commun., 2013, 4, 1181–1188 | 1185
MedChemComm Concise Articlerequired pyridazinone derivative (5–7) (0.25 mmol) in dry DMF
(2 mL) was added to a suspension of sodium hydride (7.2 
103 g, 0.3 mmol) in dry DMF at 0 C under an inert atmo-
sphere. Aer 30 min, the appropriate bromo alkyl chain (0.3
mmol) was added and the mixture was stirred for 15 h at 70 C.
Water was cautiously added dropwise to the cooled reaction
mixture to destroy the excess of sodium hydride. The mixture
was then extracted with ethyl acetate (3 2 mL) and the organic
layers were collected, dried over Na2SO4, and evaporated in
vacuo. Upon purication by ash chromatography the nal
products were obtained. (see Table 1 for data) The enantiomeric
separation of compound ()-2c was performed using a chiral
semi-preparative HPLC: Chiralcel OJ (10 mm, 250  4.6 mm),
hexane/ethanol (70 : 30), 1.0 mL min1, UV 254 nm; tR(1) ¼
1.999 min (49.9%) [a]25D 364.6 (c 0.0082, EtOH); tR(2) ¼ 3.904
min (50.1%) [a]25D + 374.4 (c 0.0082, EtOH).
General procedure B for the synthesis of 4-(3-oxo-4,4a,5,6-
tetrahydrobenzo [h] cinnolin-2(3H)-yl)carboxylic acids 2i,j. The
required ester (0.46 mmol) was dissolved in ethanol (5 mL) and
an aqueous solution of 1 N NaOH (1 mL) was added. The
solution was stirred at reux for 2 h, then the ethanol was
removed under reduced pressure and the residue was diluted
with water (5 mL) and extracted with ethyl acetate (1  2 mL).
The aqueous layer was acidied with 6 N HCl (1 mL) and
extracted with ethyl acetate (3  2 mL). The organic layer was
dried over anhydrous Na2SO4, ltered and evaporated under
reduced pressure. The crude product was puried by ash
chromatography (see Scheme 1 and Table 1).
Synthesis of N-ethyl-4-(3-oxo-4,4a,5,6 tetrahydrobenzo [h]
cinnolin-2(3H)-yl)-butanamide 2k. To a solution of compound
2j (3.7  102 g, 0.13 mmol) in dichloromethane (3 mL), the
coupling agent HATU (7.41  102 g, 0.20 mmol), ethylamine
(0.02 mL, 0.35 mmol) and N-methyl morpholine (until pH ¼ 7)
were added. The mixture was stirred at room temperature for
1 h and then washed with 1 N HCl (2  1 mL), saturated
NaHCO3 solution (2  1 mL) and nally with brine (2  1 mL).
The organic layer was separated, dried over anhydrous Na2SO4
and evaporated in vacuo. Purication by ash chromatography
aﬀorded the nal compound 2k (see Scheme 1 and Table 1).
2-(4-(Ethylamino)butyl)-4,4a,5,6-tetrahydrobenzo[h]cinnolin-
3(2H)-one 2l. To a solution of 6 (5  102 g, 0.25 mmol) in dry
DMF under a nitrogen atmosphere, NaH (7.2  103 g, 0.3
mmol) and Br(CH2)4Br (0.036 mL, 0.3 mmol) were added. The
mixture was irradiated for 10 min at 60 C in a microwave
synthesizer. The solvent was evaporated under reduced pressure
and the residue was extracted with ethyl acetate (3  2 mL). The
organic layer was separated, dried over anhydrous Na2SO4, and
evaporated in vacuo. Upon purication by ash chromatography
(eluent: petroleum ether/ethyl acetate 7 : 3) 2-(4-bromobutyl)-
4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one (9) was obtained
as a white solid. To a solution of the latter (4.6  102 g, 0.14
mmol) in DMF (2 mL), ethylamine (1.1  102 mL, 0.17 mmol)
and triethylamine (2.4  102 mL, 0.17 mmol) were added and
themixture was stirred at 50 C for 7 h. The solvent was removed
under reduced pressure and the residue diluted with water
(2 mL) and extracted with ethyl acetate (3  1 mL). The organic
layer was dried over anhydrous Na2SO4 and evaporated in vacuo.1186 | Med. Chem. Commun., 2013, 4, 1181–1188Purication by ash chromatography gave the nal compound
2l (see Scheme 1 and Table 1).
3-(3-Oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)propyl
2-amino-2-hydroxyacetate 2o. General procedure A was fol-
lowed for the synthesis of 2-(3-hydroxypropyl)-4,4a,5,6-tetrahy-
drobenzo [h] cinnolin-3(2H)-one 10 from 6. Compound 10 was
obtained as a yellow oil (53% yield) upon purication by ash
chromatography (eluent: dichloromethane/methanol 95 : 5). To a
solution of 10 (4 102 g, 0.15mmol) in dichloromethane (3mL)
N-Boc-Phe-OH (1.1  102 g, 0.40 mmol) and the coupling agent
HATU (8.8  102 g, 0.23 mmol) were added. The solution was
brought to pH¼ 7 with drops of N-methyl morpholine and it was
stirred at room temperature for 24 h. The solvent was removed
under reduced pressure, the residue diluted with dichloro-
methane (3 mL) and washed in succession with 1 N HCl (3 
1 mL), saturated solution of NaHCO3 (3  1 mL) and brine (2 
1 mL). The solvent was dried with Na2SO4 and evaporated.
The crude product was puried by ash chromatography
(eluent: dichloromethane/ethyl acetate 85 : 15) to obtain 3-(3-
oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)propyl-2-(tert-
butoxycarbonylamino)-3-phenyl propanoate 11 as a yellow oil
(33% yield). Compound 11 (3  102 g, 0.06 mmol) was dis-
solved in dichloromethane (3 mL) and the solution was cooled to
0 C with an ice bath. Triuoroacetic acid (0.05 mL, 0.71 mmol)
was slowly added and the solution was stirred at room temper-
ature for 3 h. The mixture was cooled to 0 C, treated with a
solution of 0.5 N NaOH (1 mL) and extracted with dichloro-
methane (3  1.5 mL). The organic layer was dried over anhy-
drous Na2SO4, ltered and evaporated in vacuo. Purication by
ash chromatography of the crude residue aﬀorded the nal
compound 2o (see Scheme 1 and Table 1).
Synthesis of 2-(3-(2H-tetrazol-5-yl)propyl)-4,4a,5,6-tetrahy-
drobenzo [h] cinnolin-3(2H)-one 2p. General procedure A was
followed for the synthesis of 4-(3-oxo-4,4a,5,6-tetrahydrobenzo-
[h]cinnolin-2(3H)-yl)butanenitrile 12 from 6. Compound 12 was
obtained as a white solid (67% yield) upon purication by ash
chromatography (eluent: dichloromethane/ethyl acetate 6 : 4).
A solution of 12 (5  102 g, 0.2 mmol), sodium azide (1.2 
102 g, 1.9 mmol) and zinc bromide (6.2  102 g, 0.3 mmol) in
H2O/isopropanol 2 : 1 (2 mL) was irradiated for 1 h at 170 C in a
microwave synthesizer. 6 N HCl (2 mL) was added and the
mixture was extracted with ethyl acetate (3 2 mL). The organic
layer was dried over anhydrous Na2SO4, ltered and evaporated
under reduced pressure. The crude residue was puried by ash
chromatography to give 2p (see Scheme 1 and Table 1).
Synthesis of ethyl 2-(3-oxo-5,6-dihydrobenzo[h]cinnolin-
2(3H)-yl)butanoate 4c. To a suspension of 5,6-dihydrobenzo[h]-
cinnolin-3(2H)-one 8 (ref. 11) (5 102 g, 0.25 mmol) in toluene
(1.5 mL), KOH (1.8  102 g, 0.33 mmol), TBAF$3H2O (8  103
g, 0.025 mmol) and ethyl 4-bromopropionate (0.046 mL, 0.33
mmol) were added. The mixture was heated at 50 C for 3 h and
then extracted with ethyl acetate (3  1 mL). The combined
organic extracts were washed with 5% NaOH (1 2 mL) and 5%
HCl (1  2 mL), dried over anhydrous Na2SO4, ltered and
evaporated in vacuo. The crude product was puried by ash
chromatography to obtain the nal compound 4c (see Scheme 1
and Table 1).This journal is ª The Royal Society of Chemistry 2013
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[h] cinnolin-3(2H)-one (+)-13. The enantiomeric separation of
compound ()-6 was performed using a chiral semi-preparative
HPLC: Chiralcel OJ (10 mm, 250  4.6 mm), hexane/ethanol
(70 : 30), 1.0mLmin1, UV 254 nm; tR(1)¼ 2.047min (49.9%) [a]25D
561.8 (c 0.0055, CHCl3); tR(2) ¼ 2.714 min (50.1%) [a]25D +572.7
(c 0.0055, CHCl3). To a solution of (+)-6 (5  102 mg, 0.25 mmol)
in dry DMF under a nitrogen atmosphere, NaH (7.2  103 g,
0.3 mmol) and Br(CH2)2Cl (0.025 mL, 0.3 mmol) were added. The
mixture was irradiated for 15 min at 70 C in a microwave
synthesizer. The solution was evaporated under reduced pressure
to remove the solvent and extracted with ethyl acetate (3  2 mL).
The organic layer was separated, dried over anhydrous Na2SO4,
and evaporated under reduced pressure. Upon purication by
ash chromatography (eluent: petroleum ether/ethyl acetate 7 : 3),
(+)-13 was obtained as a white solid (76% yield). M.p. 127–128 C.
Synthesis of ()-ethyl-4-(3-oxo-4,4a,5,6 tetrahydrobenzo [h]
cinnolin-2(3H)-yl)butanoate ()-2c. Compound ()-2c was
synthesized by alkylation of ()-6 (5  103 g, 0.025 mmol)
with Br(CH2)3COOEt (0.004 mL, 0.03 mmol), following the
same procedure as that used to obtain (+)-13 (80% yield).
Characterization of ()-2c was performed using a chiral
analytical HPLC: Lux cellulose-3 (3 mm, 50  4.6 mm), hexane/
ethanol (70 : 30), 0.8 mL min1, UV 254 nm; tR ¼ 1.571 min.
The result showed that the reaction occurred with less than
10% of racemization.‡ The supplementary crystallographic data have been deposited at the Cambridge
Crystallographic Data Centre: CCDC deposition number 906024. These data can
be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or
from CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033;
deposit@ccdc.cam.ac.uk).Biological assays
Dual-luciferase assay
Cell culture. Human colon cancer cell line (HCT-116), from
American Type Culture Collection, was maintained in McCoy's
5A (Gibco/BRL). The culture medium was supplemented with
10% heat-inactivated fetal bovine serum (Gibco/BRL). Cell
cultures were maintained at 37 C under a humidied atmo-
sphere of 5% CO2 in an incubator.
Transient transfection and dual-luciferase assays.17 HCT-116
cells were seeded at a density of 10  105 cells in a 100 mm2
culture plate. The cells were co-transfected with pSTAT3-TA-Luc
(27 mg per plate) and the internal control plasmid pRL-TK (9 mg
per plate) containing the Renilla luciferase gene. All plasmids
used in this experiment were purchased from Promega. The
transfection was carried out using TransFectin (Bio-Rad)
according to the manufacturer's protocol. Aer 5 h of trans-
fection, the cells were trypsinized and seeded onto sterilized
black bottom 96-well plates at a density of 1  104 cells per well.
On the following day, cells were treated with test compounds
and incubated for 24 h. Firey and Renilla luciferase activities
were measured using a dual-light reporter gene assay kit
(Promega) on Wallac Victor2 (Perkin-Elmer, Inc., Wellesley,
MA). The Renilla luciferase activity was determined to calibrate
the transfection eﬃciency and cytotoxicity of chemicals. The
relative STAT3 activity was calculated by dividing the rey
luciferase activity with the Renilla luciferase activity in each
transfection experiment. The values of STAT3 inhibitory activity
were the means of 3 experiments and the maximum deviation
from the mean was less than 10%.This journal is ª The Royal Society of Chemistry 2013Alphascreen-based assay. AlphaScreen is a bead-based
nonradioactive assay system for detecting biomolecular inter-
actions in a microtiter plate format. Binding of biological
partners brings donor and acceptor beads into close proximity
and as a result, a uorescent signal between 520 and 620 nm is
produced. The alphaScreen-based assays18 were performed in a
nal reaction volume of 25 mL of the assay buﬀer containing
10 mM HEPES–NaOH (pH 7.4), 50 mM NaCl, 1 mM EDTA (pH
8.0), 0.1% NP-40, and 10 ng mL1 BSA in a 96-well microtiter
plate at 25 C. Phospho-Tyr (pTyr) peptide probes used in this
study were 5-carboxyuorescein (FITC)-GpYLPQTV for STAT3,
FITC-GpYDKPHVL for STAT1, and FITC-PSpYVNVQN for Grb2.
Firstly, 75 nM of each SH2-containing protein was incubated
with the test compound for 15 min. Each protein sample was
then incubated for 90 min with 50 nM of its corresponding
FITC-pTyr peptide, and mixed with streptavidin coated donor
beads and anti-FITC acceptor beads simultaneously before
detection at 570 nm using EnVison Xcite (PerkinElmer).Computational methods
All calculations were performed using the Gaussian09 program
package,23 at the B3LYP/6-311+G(d,p) level.24 Theoretical values
of [a]D were obtained at the same level of theory specifying
appropriate keywords (polar and cphf) into the Gaussian input.X-ray crystallography
Crystals of (+)-13 were grown by slow evaporation of a meth-
anolic solution. Suitable single crystals were mounted on a glass
ber on a CAD4 diﬀractometer with graphite monochromated
MoKa radiation (l 0.71073 A˚). The cell parameters were deter-
mined and rened by least-squares t of 25 high angle reec-
tions. The structure was resolved by direct methods using Sir-92
(ref. 25) and completed by iterative cycles of full-matrix least
squares renement on Fo
2 and DF synthesis using the SHELXL-97
program (WinGX suite).26 All non-H-atoms were rened aniso-
tropically. The H-atoms of (+)-13 were detected in the Fourier
map. Geometrical calculations were carried out with the program
PARST.27 The absolute conguration of (+)-13was unambiguously
determined by rening the Flack parameter (0.04(15)), exploit-
ing the anomalous scattering eﬀects of chlorine.28‡ Crystal data
for (+)-13: C14 H15 N2 O1 Cl1,Mr ¼ 262.73 g mol1, orthorhombic,
space group P212121, a¼ 7.929(4) A˚, b¼ 12.530(4) A˚, c¼ 12.977(8)
A˚, V¼ 1289.3(8) A˚3, Z¼ 4,Dcalc¼ 1.354mgm3, F(000)¼ 552, R¼
0.041 (reections collected/unique ¼ 1825/1806), wR2 ¼ 0.095,
T ¼ 293(2) K, GOF ¼ 0.948. The reections were collected in the
range of 2.26 # q# 24.97 (limiting indices¼1# h# 9,1#
k# 14,1# l# 15) employing a 0.9 0.4 0.3 mm crystal. The
residual positive and negative electron densities in the nal map
were 0.142 and –0.244 e A˚3, respectively.Med. Chem. Commun., 2013, 4, 1181–1188 | 1187
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